Interventional Cardiology News and Research

RSS

FDA approves Medtronic's Integrity Coronary Stent System

Delivering another innovation for interventional cardiology, Medtronic, Inc.,announced today the U.S. Food and Drug Administration (FDA) approval of the Integrity Coronary Stent System. The new platform for Medtronic's coronary stents, including the Integrity bare-metal stent, is based on an advance in biomedical engineering called continuous sinusoid technology that enables the exploration of other breakthrough device concepts such as a polymer free drug filled stent.

21 Sep 2010

St. Joseph's Hospital-North adds obstetric services

Moms-to-be have asked for it and now St. Joseph's Hospital-North delivers a birthing experience like no other hospital stay. The area's first new hospital in more than 30 years has added obstetric services, bringing new moms and babies comfortable care in a soothing, elegant environment.

17 Sep 2010

Optical coherence tomography to penetrate intravascular ultrasound market: MRG

According to Millennium Research Group (MRG), the optical coherence tomography market will grow at an annual rate of almost 60% through 2015, spurred by physician adoption of this new technology that was launched in the US in May 2010.

16 Sep 2010

Tryton Medical closes $20 million Series D round of financing

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company has closed a $20 million Series D round of financing.

14 Sep 2010

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

3 Sep 2010

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".

31 Aug 2010

International Symposium to explore Hybrid approach for congenital heart disease

Interventional cardiologists and cardiothoracic surgeons throughout the United States and the world, who treat patients with congenital heart disease, will gather at the Hilton Columbus at Easton Town Center August 31-September 2, 2010 for the International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC).

31 Aug 2010

Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications

With both bleeding und thrombotic complications having a negative effect on PCI outcomes, increasing efforts have been made to improve PCI anticoagulation regimens. Although unfractionated heparin has been the standard anti-thrombotic agent in interventional cardiology for decades, there is still no solid evidence from large clinical trials to guide its dosing during PCI.

31 Aug 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

A significant milestone has been reached in the development of a new therapy for patients suffering from coronary artery disease. On July 27, 2010 the BIOTRONIK DREAMS (Drug Eluting Absorbable Metal Scaffold) was successfully implanted in the first patient by Prof. Dr. Michael Haude at the Lukaskrankenhaus in Neuss, Germany as part of the first-in-man clinical study BIOSOLVE-I.

13 Aug 2010

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

Boston Scientific Corporation today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S., Ph.D., Professor and Director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.

4 Aug 2010

KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

KIKA™ Clinical Solutions is on track for unprecedented 2010 growth. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.

26 Jul 2010

Clinical research updates on interventional cardiology techniques that affect patient care

TCT 2010 will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

21 Jul 2010

St. Jude Medical acquires LightLab Imaging

St. Jude Medical, Inc., a global medical device company, today completed the previously announced acquisition of LightLab Imaging, Inc. for approximately $90 million in cash.

7 Jul 2010

Lack of reimbursements limit drug-eluting stent market across Latin America

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite the rising popularity of drug-eluting stents (DES) across Latin America, bare-metal stents (BMS) will continue to represent a significant portion of the overall coronary stent market through 2014. This trend is especially evident in Brazil, where the public healthcare system does not provide any reimbursement for DES procedures.

30 Jun 2010

Tryton announces first three implants of Side Branch Stent System in Israel

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the company's TRYTON Side Branch Stent™ System has been used in three cases in Israel for the first time.

24 Jun 2010

Medical Simulation announces new agreement with New York's North Shore-LIJ Health System

Medical Simulation Corporation (MSC) proudly announces a new agreement with the North Shore-LIJ Health System, New York's largest health system and recipient of the 2010 National Quality Healthcare Award from the National Quality Forum. The agreement includes the sale of MSC's endovascular simulation system, Simantha®, and licensing of MSC's curriculum and training services to advance North Shore's education and patient safety goals over the next three years.

18 Jun 2010

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased coronary tissue and guide therapeutic interventions, today announced that its next-generation LipiScan IVUS Coronary Imaging System will be featured at EuroPCR 2010, an international educational conference focused on introducing the latest techniques, updates and breakthrough science to the interventional cardiology community.

27 May 2010

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).

26 May 2010

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

Boston Scientific Corporation today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research (ISR) study designed to compare the performance of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System to the XIENCE PRIME™ Everolimus-Eluting Coronary Stent System.

26 May 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

26 May 2010

Interventional Cardiology News and Research

FDA approves Medtronic's Integrity Coronary Stent System

St. Joseph's Hospital-North adds obstetric services

Optical coherence tomography to penetrate intravascular ultrasound market: MRG

Tryton Medical closes $20 million Series D round of financing

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

International Symposium to explore Hybrid approach for congenital heart disease

Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

Clinical research updates on interventional cardiology techniques that affect patient care

St. Jude Medical acquires LightLab Imaging

Lack of reimbursements limit drug-eluting stent market across Latin America

Tryton announces first three implants of Side Branch Stent System in Israel

Medical Simulation announces new agreement with New York's North Shore-LIJ Health System

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News